Skip to Content

Join the 'Agrylin' group to help and get support from people like you.

Agrylin News

FDA Medwatch Alert: Agrylin (anagrelide hydrochloride)

Posted 9 Feb 2005 by

Shire and FDA notified healthcare professionals about changes to the CONTRAINDICATIONS and WARNINGS sections of the prescribing information for Agrylin (anagrelide hydrochloride), a medication approved for the treatment of thrombocythemia secondary to myeloproliferative disorders to reduce platelet count and the risk of thrombosis and to ameliorate associated symptoms including thrombohemorrhagic events. Pharmacokinetic studies have revealed an 8-fold increase in total exposure (AUC) to anagrelide hydrochloride in patients with moderate hepatic impairment. Use of anagrelide hydrochloride has not been studied in patients with severe hepatic impairment. Labeling changes include the contraindication to the use of Agrylin in patients with severe hepatic impairment. The WARNINGS section describes the need for dosage reduction in patients with moderate hepatic impairment and the necessity of ... Read more

Related support groups: Agrylin

Ask a Question

Further Information

Related Condition Support Groups

Thrombocythemia, Chronic Myelogenous Leukemia (CML)

Agrylin Patient Information at